Publications

Nature communications

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

24-06-2026

Cancer discovery

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

01-06-2026

Scientific reports

Crowdsourcing enables robust cell annotation for breast cancer pathology.

11-05-2026

Genome medicine

The contribution of rare germline variants to the immune landscape of breast cancer.

09-05-2026

Histopathology

Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on behalf of the International Immuno-Oncology Biomarker Working Group.

01-05-2026

Nature communications

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

01-04-2026

Nature cancer

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

01-03-2026

iScience

Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer.

20-02-2026

The American journal of surgical pathology

Performance Assessment of a Deep Learning-based Algorithm for Ovarian Cancer Histotyping in an Independent Data Set.

01-02-2026

Nature

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

01-01-2026

The Lancet. Digital health

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

01-11-2025

Research square

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

03-10-2025

medRxiv : the preprint server for health sciences

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

22-09-2025

NPJ digital medicine

H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.

02-07-2025

Nature communications

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

14-04-2025

Annals of diagnostic pathology

Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank.

01-02-2025

bioRxiv : the preprint server for biology

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

28-01-2025

Biopreservation and biobanking

The Information Technology (IT) Infrastructure of the Multicenter Archipelago of Ovarian Cancer Research Biobank: A Potential Blueprint for Other Biobanks.

01-12-2024

Nature communications

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

07-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

The oncologist

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.

06-09-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

British journal of cancer

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

01-08-2024

JAMA oncology

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

01-08-2024

NPJ digital medicine

PatchSorter: a high throughput deep learning digital pathology tool for object labeling.

20-06-2024

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.

06-05-2024

NPJ breast cancer

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.

18-04-2024

The Journal of pathology

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.

01-03-2024

Research square

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer.

14-11-2023

Breast cancer research : BCR

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

13-11-2023

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Breast cancer research : BCR

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

04-10-2023

JCO precision oncology

Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.

01-09-2023

Cell reports. Medicine

RadioLOGIC, a healthcare model for processing electronic health records and decision-making in breast disease.

15-08-2023

The Journal of pathology

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

01-08-2023

The Journal of pathology

Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

01-08-2023

Breast (Edinburgh, Scotland)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

01-08-2023

Breast cancer research : BCR

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

19-06-2023

NPJ breast cancer

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

13-05-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

NPJ breast cancer

Predicting breast cancer types on and beyond molecular level in a multi-modal fashion.

22-03-2023

Cancer

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

01-03-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Cell reports. Medicine

HRD-related morphology discovery in breast cancer by controlling for confounding factors.

20-12-2022

Cancers

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

02-12-2022

Gynecologic and obstetric investigation

Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research: Archipelago of Ovarian Cancer Research.

01-12-2022

NPJ breast cancer

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.

08-11-2022

International journal of cancer

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

15-10-2022

NPJ breast cancer

Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ.

15-09-2022

Nature communications

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.

05-08-2022

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

Crowdsourcing enables robust cell annotation for breast cancer pathology.

The contribution of rare germline variants to the immune landscape of breast cancer.

Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on behalf of the International Immuno-Oncology Biomarker Working Group.

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.

Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer.

Performance Assessment of a Deep Learning-based Algorithm for Ovarian Cancer Histotyping in an Independent Data Set.

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation.

Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.

H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank.

Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition.

The Information Technology (IT) Infrastructure of the Multicenter Archipelago of Ovarian Cancer Research Biobank: A Potential Blueprint for Other Biobanks.

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancer.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

PatchSorter: a high throughput deep learning digital pathology tool for object labeling.

Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.

Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.

The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer.

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning.

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.

RadioLOGIC, a healthcare model for processing electronic health records and decision-making in breast disease.

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Predicting breast cancer types on and beyond molecular level in a multi-modal fashion.

CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

HRD-related morphology discovery in breast cancer by controlling for confounding factors.

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research: Archipelago of Ovarian Cancer Research.

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ.

Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.

This site uses cookies